Clinical Trial Update: Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib S-malate in patients with metastatic or unresectable pheochromocytoma or paraganglioma; results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-31